Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metforminin Patients with Type2 Diabetes Mellitus in Mexico
Neslusan C, Teschemaker A, Johansen P, Willis M, Valencia-Mendoza A and Puig A
The validated IHE model (Economic and Health Outcomes [ECHO]-T2DM) was used to estimate the cost-effectiveness of canagliflozin versus sitagliptin for the treatment of type 2 diabetes mellitus (T2DM) as an add-on to metformin in Mexico. Data from a head-to-head, phase III clinical trial were used to simulate outcomes and resource use over 20 years. The results showed that canagliflozin (both 100 and 300 mg) was likely to be cost-effective versus sitagliptin in patients with T2DM who have inadequate glucose control on metformin, from the perspective of the Mexican health care system.
Value in Health Regional Issues 2015; 8: 8-19
DOI: https://doi.org/10.1016/j.vhri.2015.01.002